Click Here to
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on February 18, 2020 in ESMO
“Data from 3 clinical trials with various enrollment criteria and that used different PARP inhibitors, 2 of which used a PARP inhibitor plus bevacizumab, led to the same conclusion of the need to expand the use of PARP inhibition in ovarian cancer to all patients. These trials show that the PARP inhibition era is here.”
Web Exclusives published on February 18, 2020 in Biosimilars

It is estimated that 350 million people worldwide use biologics on a regular basis to treat their medical conditions. These therapies are incredibly innovative and have expanded the arsenal of effective treatment options for cancer, rheumatoid arthritis, and other serious illnesses. However, the high costs of these therapies, although understandable, can create access issues for patients. That is why biosimilars are so important.

Web Exclusives published on February 14, 2020 in Ovarian Cancer
Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020.
Web Exclusives published on February 14, 2020 in Ovarian Cancer
The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes.
Web Exclusives published on February 14, 2020 in Ovarian Cancer
Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level.
Web Exclusives published on February 14, 2020 in Ovarian Cancer
Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately.
Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo.
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020.
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
On January 23, 2020, the FDA granted accelerated approval to tazemetostat (Tazverik; Epizyme), a methyltransferase inhibitor, for the treatment of metastatic or locally advanced epithelioid sarcoma in adults and pediatric patients aged ≥16 years who are not eligible for complete resection.
Web Exclusives published on January 24, 2020 in Ovarian Cancer
Results from 3 clinical trials demonstrate the value of PARP inhibitors as first-line or maintenance therapies in patients with advanced ovarian cancer.
Page 5 of 22
Results 41 - 50 of 219